Chemistry breakthrough has potential to make more effective cancer drugs with less harmful side effects
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Jul-2025 17:11 ET (28-Jul-2025 21:11 GMT/UTC)
Chemists have discovered for the first time a unique way to control and modify a type of compound widely used in medicines, including a drug used to treat breast cancer.
Chronic inflammation occurs when the immune system is stuck in attack-mode, sending cell after cell to defend and repair the body for months or even years. Diseases associated with chronic inflammation, like arthritis or cancer or autoimmune disorders, weigh heavily on human health—and experts anticipate their incidence is on the rise. A new study by investigators from Mass General Brigham identified a protein called WSTF that could be targeted to block chronic inflammation. Crucially, this strategy would not interfere with acute inflammation, allowing the immune system to continue responding appropriately to short-term threats, such as viral or bacterial infection. Results are published in Nature.
A team led by researchers at Baylor College of Medicine and Washington University School of Medicine has shed light on the process that drives Barrett’s esophagus formation. This condition affects the lining of the esophagus – the tube that carries food from the mouth to the stomach – and increases the risk of developing esophageal adenocarcinoma, a serious and often deadly cancer.
The study reveals that two important genes involved in guiing and maintaining the identity of the esophagus and intestine, SOX2 and CDX2, are altered in Barrett’s esophagus. The findings not only deepen our understanding of how the disease develops but also open the door to new ways of identifying people at risk and potentially preventing the condition from progressing to cancer.
Using an inexpensive electrode coated with DNA, MIT researchers designed disposable diagnostics that could be adapted to detect a variety of diseases, including cancer or infectious diseases such as influenza and HIV.
During therapy, some cancer cells evolve to escape elimination. Newer anticancer drugs that can overcome this resistance are necessary. Now, researchers from Japan demonstrate that aromatic benzaldehyde inhibits the growth of therapy-resistant pancreatic cancer. By preventing various signaling proteins and histone modifiers like Ser28-phosphorylated histone H3 (H3S28ph) from binding to 14-3-3ζ protein, benzaldehyde overcomes therapy resistance and blocks plasticity to prevent the spread of cancer. These findings highlight its potential in cancer treatment.